Sartorius Stedim Biotech and Repligen Corporation Partner to Introduce Next-Generation Perfusion-Enabled Bioreactors
Repligen Corporation (RGEN)
Last repligen corporation earnings: 2/20 07:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
repligen.com/investors
Company Research
Source: GlobeNewswire
Development collaboration integrates Sartorius Stedim Biotech’s BIOSTAT® STR bioreactors and Repligen’s XCell™ ATF cell retention control technologyCustomers to benefit from simplified, scalable solutions for intensified cell culture GÖTTINGEN, Germany and WALTHAM, Mass., Sept. 04, 2018 (GLOBE NEWSWIRE) -- Sartorius Stedim Biotech (SSB) (Euronext: DIM), a leading international supplier for the biopharmaceutical industry, and Repligen Corporation (NASDAQ:RGEN), a global life sciences company focused on bioprocessing technologies, have entered into a collaboration agreement to integrate Repligen’s XCell™ ATF cell retention control technology into SSB’s BIOSTAT® STR large-scale single-use bioreactors to create novel perfusion-enabled bioreactors. As a result of this collaboration, end users will stand to benefit from a single control system for 50 L to 2,000 L bioreactors used in perfusion cell culture applications. This single interface is designed to control cell growth, fluid manag
Show less
Read more
Impact Snapshot
Event Time:
RGEN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RGEN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RGEN alerts
High impacting Repligen Corporation news events
Weekly update
A roundup of the hottest topics
RGEN
News
- We Discuss Why Repligen Corporation's (NASDAQ:RGEN) CEO Compensation May Be Closely Reviewed [Yahoo! Finance]Yahoo! Finance
- Repligen Corporation to Present at Upcoming May Investor Conferences [Yahoo! Finance]Yahoo! Finance
- Repligen Corporation to Present at Upcoming May Investor ConferencesGlobeNewswire
- Repligen First Quarter 2024 Earnings: EPS Misses Expectations [Yahoo! Finance]Yahoo! Finance
- Repligen Co. (NASDAQ: RGEN) had its price target lowered by analysts at JPMorgan Chase & Co. from $230.00 to $200.00. They now have an "overweight" rating on the stock.MarketBeat
RGEN
Earnings
- 5/1/24 - Miss
RGEN
Sec Filings
- 5/3/24 - Form DEFA14A
- 5/1/24 - Form 10-Q
- 5/1/24 - Form 8-K
- RGEN's page on the SEC website